Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. Issue 2 (21st January 2015)

• Record Type: Journal Article
• Authors: Hendy, Philip; Hart, Ailsa; Irving, Peter
• Is Part Of: Frontline gastroenterology. Volume 7:Issue 2(2016)
• Page Start: 122
• Page End: 128
• Publication Date: 2015-01-21
• Subjects: INFLIXIMAB -- CROHN'S DISEASE -- IBD -- ULCERATIVE COLITIS -- DRUG METABOLISM; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2014-100527
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : The antitumour necrosis factor (TNF) medications, adalimumab and infliximab, play an important role in the management of both Crohn's disease and ulcerative colitis. For those in whom anti-TNF is effective, the therapy is associated with fewer symptoms, improved quality of life and disease and surgery-free survival. Unfortunately, up to 30% of patients will fail to respond to anti-TNF drugs while up to 50% of those who do see an initial response will lose response at some point. The introduction of drug monitoring for anti-TNFs, including drug level and antidrug antibody level testing allows a more personalised management of patients and improves patient outcomes. This article reviews the data for the use of anti-TNF monitoring and presents a 'how to' guide for clinicians.